Immune checkpoint blockade therapy in head and neck cancer: a review

Authors

  • Shajedul Islam Division of Disease Control and Molecular Epidemiology, Department of Dental Public Health, City Dental College and Hospital, Dhaka
  • Md Shahed Rafi Pavel Associate Professor, Department of Dental Public Health, City Dental College and Hospital, Dhaka
  • Syed Taufiqul Islam Division of Pediatric Dentistry, Health Sciences University of Hokkaido, 1757 Kanazawa Ishikari Tobetsu, Hokkaido 061-0293, Japan
  • Nazmus Shalehin Division of Histology, School of Dentistry, Health Sciences University of Hokkaido, 1757 Kanazawa Ishikari Tobetsu, Hokkaido 061-0293, Japan
  • Shahed Jahan Babu Associate Professor, Department of Dental Public Health, Update Dental College and Hospital, Dhaka

DOI:

https://doi.org/10.3329/updcj.v8i2.40384

Keywords:

PD1; PDL-1; CTLA4; MHC; T cell, APC.

Abstract

Head and neck cancer (HNC) is a common malignant tumor, carrying a poor prognosis, and despite advances in oncology, this rate has not improved significantly for decades. It has recently been evaluated that the immunologic checkpoint inhibitors become a novel promising strategic immunotherapy in the treatment of metastatic cancer. Therefore, our current review article will discuss the biological role and impact of the immune checkpoint inhibitor in HNC.

Update Dent. Coll. j: 2018; 8 (2): 30-33

Downloads

Download data is not yet available.
Abstract
543
PDF
400

Downloads

Published

2018-12-25

How to Cite

Islam, S., Pavel, M. S. R., Islam, S. T., Shalehin, N., & Babu, S. J. (2018). Immune checkpoint blockade therapy in head and neck cancer: a review. Update Dental College Journal, 8(2), 30–33. https://doi.org/10.3329/updcj.v8i2.40384

Issue

Section

Review Articles